Table 2. Characteristics of other relevant studies included in the pooled-analysis.
| Source | Scope | Treatment | Sample size | Median age (range) in years | Summary statistics on survival (months) | Criteria for start time for PFS or OS |
|---|---|---|---|---|---|---|
| Tournigand, 2015 (DREAM; OPTIMOX) | Multicenter, France, Austria, and Canada |
Induction: (BEV + mFOLFOX7/XELOX2/FOLFIRI)/*12 weeks; Maintenance: Arm 1: BEV*3 weeks; Arm 2: BEV *3 weeks + Erlo |
Arm 1: 228 Arm 2: 224 |
Arm 1: 63 (57–70) Arm 2: 63 (57–70) |
Arm 1: PFS, 4.9 (4.1–5.7); OS, 22.1 (19.6–26.7) Arm 2: PFS, 5.4 (4.1–5.7); OS, 24.9 (21.4–28.9) |
PFS: From date of maintenance randomization to first PD. OS: From date of maintenance randomization to death. |
| Tveit 2012 (NORDIC VII) | Multicenter, Norway, Sweden, Denmark, Iceland |
Induction: (Cet+ FLOX)/FLOX every 2 weeks *8 cycles; Arm A: FLOX until PD or unacceptable toxicity; Arm B: Cet plus FLOX until PD or unacceptable toxicity; Arm C: Cet; reintroduce FLOX at PD |
Arm A: 185 Arm B: 194 Arm C: 187 |
Arm A: 61.2 (29.9–74.8) Arm B: 60.8 (24.1–74.4) Arm C: 63.6 (33.1–74.9) |
Arm A: PFS, 7.9 (7.3–8.5); OS, 20.4 (17.0–23.7) ArmB: PFS, 8.3 (7.4–9.3); OS, 19.7 (15.9–23.5) Arm C: PFS, 7.3 (6.8–7.9); OS, 20.3 (17.3–23.3) |
PFS: From random assignment to the first recorded PD or death. |
| Johnsson 2013 (Nordic ACT) | Multicenter, Denmark, Sweden |
Induction: (XELOX/XELIRI+BEV) every 3 weeks *6 cycles or (FOLFOX/FOLFIRI+BEV) every 2 weeks *9 cycles; Maintenance: Arm1: BEV *3 weeks; Arm2: BEV *3 weeks + Erlo. |
Arm 1: 79 Arm 2: 80 |
Arm 1: 65 (43–82) Arm 2: 64 (48–80) |
Arm 1: PFS, 4.23; OS, 22.8 (16.6–25.3) Arm 2: PFS, 5.73; OS, 21.5 (15.4–28.3) |
PFS, OS: From start of maintenance treatment. |
| Waddell 2011 (XelQuali) | Single-arm, Two centers, UK |
Induction: XELOX every 3 weeks *4 cycles Maintenance: Cape *3 weeks |
35 | 58 (38–79) | PFS, 8.1 (6.2–11.8) OS, 23.1 (17.8–28.5) |
PFS: From the first day of treatment to first evidence of clinical/radiological PD or death. OS: From registration to death from any cause. |
| Nakayama 2011 (CCOG-070) | Single-arm, Japan |
Induction: mFOLFOX6 every 2 weeks *6 cycles Maintenance: Oral S-1 |
21 | 58 (38–79) | PFS, 7.9; DDC, 9.3; OS, NR | DDC defined as PFS, or, addition of the initial PFS and the PFS of the reintroduction. |
Abbreviations: BEV = Bevacizumab; Cape = capecitabine; Erlo = erlotinib; Cet = cetuximab; CFI = chemotherapy-free interval; FLOX = 5-FU/leucovorin/oxaliplatin; FOLFOX = folinic acid (leucovorin)/5-FU/oxaliplatin; XELOX = capecitabine/oxaliplatin; XELIRI = capecitabine/Irinotecan; m = modified; mos = months; NR = not reported; PD = disease progression; 5FU = 5-fluorouracil; PFS = progression-free survival; OS = overall survival; DDC = duration of disease control.